Clinical Trial Update: A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis [Phase 2, Phase 3]

View source ↗

Summary

A pediatric study of rozanolixizumab for moderate to severe generalized myasthenia gravis is ongoing (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• Rozanolixizumab

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Generalized Myasthenia Gravis | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING